ESH CLL 2022 | The role of the protein MARCKS in CLL response to BTK inhibitors
Lukas Frenzel, MD, University of Cologne, Cologne, Germany, discusses some recent research investigating the role of the myristoylated alanine-rich C-kinase substrate (MARCKS) protein in chronic lymphocytic leukemia (CLL). Dr Frenzel first provides some background information on the differential expression of MARCKS observed in both mutated and unmutated CLL patients. Dr Frenzel then explains a study which used proteomic analysis and gene expression data sets to further investigate the effects of low and high expression of this protein in CLL patients. Following this, Dr Frenzel explains the link between the MARCKS protein and B-cell receptor signaling, and how this protein appears to play a role in patient response to acalabrutinib and other Bruton’s tyrosine kinase (BTK) inhibitors. To conclude, Dr Frenzel states that further research is needed in this area to improve treatment approaches in CLL. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Disclosures
Abbvie Advisory board
